Showing papers on "Chronic wound published in 2023"
TL;DR: A wearable bioelectronic system that wirelessly and continuously monitors the physiological conditions of the wound bed via a custom-developed multiplexed multimodal electrochemical biosensor array and performs noninvasive combination therapy through controlled anti-inflammatory antimicrobial treatment and electrically stimulated tissue regeneration is introduced in this article .
Abstract: Chronic nonhealing wounds are one of the major and rapidly growing clinical complications all over the world. Current therapies frequently require emergent surgical interventions, while abuse and misapplication of therapeutic drugs often lead to an increased morbidity and mortality rate. Here, we introduce a wearable bioelectronic system that wirelessly and continuously monitors the physiological conditions of the wound bed via a custom-developed multiplexed multimodal electrochemical biosensor array and performs noninvasive combination therapy through controlled anti-inflammatory antimicrobial treatment and electrically stimulated tissue regeneration. The wearable patch is fully biocompatible, mechanically flexible, stretchable, and can conformally adhere to the skin wound throughout the entire healing process. Real-time metabolic and inflammatory monitoring in a series of preclinical in vivo experiments showed high accuracy and electrochemical stability of the wearable patch for multiplexed spatial and temporal wound biomarker analysis. The combination therapy enabled substantially accelerated cutaneous chronic wound healing in a rodent model.
4 citations
TL;DR: In this article , a 3D-bioprinted hydrogel scaffold was used to promote chronic diabetic wound healing by using a simple mixing of benzaldehyde and cyanoacetate group-functionalized dextran solutions.
4 citations
TL;DR: In this article , a bilayer-type cryogel made up of chitosan-gelatin as base layer for housing the bioactive factors (nitric oxide nanoparticles as signaling molecule, cerium oxide microparticles as antioxidant, calcium peroxide microparticle as oxygen releasing moiety) has been fabricated using the Cryogelation method along with a top iodine embedded antibacterial layer.
3 citations
TL;DR: In this paper , the authors provide the most recent research progress and prospect on the application of different nanomaterials in chronic wound healing, particularly focusing on their effects on intracellular factors.
1 citations
TL;DR: In this paper , the mesenchymal stem cells (MSC-sEVs) are used to regulate the cellular behavior to participate in the process of inflammatory response, angiogenesis, re-epithelization, and scarless healing.
Abstract: Chronic non-healing wounds have posed a severe threat to patients mentally and physically. Behavior dysregulation of remaining cells at wound sites is recognized as the chief culprit to destroy healing process and hinders wound healing. Therefore, regulating and restoring normal cellular behavior is the core of chronic non-healing wound treatment. In recent years, the therapy with mesenchymal stem cells (MSCs) has become a promising option for chronic wound healing and the efficacy has increasingly been attributed to their exocrine functions. Small extracellular vesicles derived from MSCs (MSC-sEVs) are reported to benefit almost all stages of wound healing by regulating the cellular behavior to participate in the process of inflammatory response, angiogenesis, re-epithelization, and scarless healing. Here, we describe the characteristics of MSC-sEVs and discuss their therapeutic potential in chronic wound treatment. Additionally, we also provide an overview of the application avenues of MSC-sEVs in wound treatment. Finally, we summarize strategies for large-scale production and engineering of MSC-sEVs. This review may possibly provide meaningful guidance for chronic wound treatment with MSC-sEVs.
1 citations
TL;DR: In this article , the authors discuss the therapeutic potential, pharmacological importance, and current clinical status of various phytoconstituents-based topical formulations as well as their associated molecular mechanisms in chronic wound management.
1 citations
TL;DR: In this article , a biodegradable drug-loaded microneedle (MN) patch is designed for biofilm eradication and chronic wound repair, which can significantly improve the specific targeting ability of the antimicrobial peptide to bacteria.
1 citations
TL;DR: The Lubbock chronic wound biofilm (LCWB) model as discussed by the authors is an in vitro model developed to mimic the pathogen colonization and the biofilm formation of a real chronic wound, and it is suitable to screen the antibacterial activity of innovative compounds.
Abstract: Chronic wounds have harmful effects on both patients and healthcare systems. Wound chronicity is attributed to an impaired healing process due to several host and local factors that affect healing pathways. The resulting ulcers contain a wide variety of microorganisms that are mostly resistant to antimicrobials and possess the ability to form mono/poly-microbial biofilms. The search for new, effective and safe compounds to handle chronic wounds has come a long way throughout the history of medicine, which has included several studies and trials of conventional treatments. Treatments focus on fighting the microbial colonization that develops in the wound by multidrug resistant pathogens. The development of molecular medicine, especially in antibacterial agents, needs an in vitro model similar to the in vivo chronic wound environment to evaluate the efficacy of antimicrobial agents. The Lubbock chronic wound biofilm (LCWB) model is an in vitro model developed to mimic the pathogen colonization and the biofilm formation of a real chronic wound, and it is suitable to screen the antibacterial activity of innovative compounds. In this review, we focused on the characteristics of chronic wound biofilms and the contribution of the LCWB model both to the study of wound poly-microbial biofilms and as a model for novel treatment strategies.
1 citations
28 Apr 2023
TL;DR: In this article , a gene liposome nanocomplex-loaded dermal substitute (GDS) has been developed as a potential solution for chronic diabetic wound treatment, which can deliver genes and therapeutic agents specifically to the wound site, promoting angiogenesis and accelerating the wound healing process.
Abstract: The incidence of chronic diabetic wounds is increasing with the growing number of diabetic patients, and conventional wound dressings have proven to be ineffective in treating them. To address this challenge, researchers have developed artificial dermal substitutes using collagen and hyaluronic acid, which are crucial extracellular matrices. However, these subsitiues lack precision and targeted treatment. To overcome this limitation, a gene liposome nanocomplex-loaded dermal substitute (GDS) has been developed as a potential solution. This innovative biomaterial combines the benefits of liposome nanocomplexes with dermal substitutes to offer a more accurate and effective treatment option for chronic diabetic wounds. The GDS has the ability to deliver genes and therapeutic agents specifically to the wound site, promoting angiogenesis and accelerating the wound healing process. Overall, the GDS presents a promising new approach for the clinical treatment of chronic diabetic wounds, offering a targeted and effective solution for this growing problem.
TL;DR: In this paper , the authors explored the role of an SAP, SCIBIOIII, with a special nanofibrous structure mimicking the natural extracellular matrix for chronic diabetic wound repair.
Abstract: An important clinical challenge is improving the healing rate of diabetic chronic wounds, and developing new approaches that can promote chronic wound healing is essential. A new biomaterial that has demonstrated great potential for tissue regeneration and repair is self-assembling peptides (SAPs); however, they have been less studied for the treatment of diabetic wounds. Here, we explored the role of an SAP, SCIBIOIII, with a special nanofibrous structure mimicking the natural extracellular matrix for chronic diabetic wound repair. The results showed that the SCIBIOIII hydrogel in vitro has good biocompatibility and can create a three-dimensional (3D) culture microenvironment for the continuous growth of skin cells in a spherical state. The SCIBIOIII hydrogel in diabetic mice (in vivo) significantly improved wound closure, collagen deposition, and tissue remodeling and enhanced chronic wound angiogenesis. Thus, the SCIBIOIII hydrogel is a promising advanced biomaterial for 3D cell culture and diabetic wound tissue repair.
TL;DR: In this paper , a wound is deemed chronic when its volume has not decreased by 50% in the end of four weeks or its size not decreased 10 - 15% per week.
Abstract: Today, chronic wounds continue to be a problem for patients and in the budget expenditures allocated to health by countries. Although chronic wounds occur due to predisposan factors, they are mainly caused by deterioration in the healing process of the skin. According to the definition that has gained prominence recently, a wound is deemed chronic when its volume has not decreased by 50% in the end of four weeks or its size not decreased 10 - 15% per week.1 With the prolongation of the average life expectancy and the increase in diseases such as diabetes mellitus, peripheral vascular diseases, pressure ulcers and chronic complications, the incidence of chronic wounds that impair skin integrity has also increased.
TL;DR: In the management of chronic wounds, the concept of wound hygiene has emerged to effectively manage biofilms, an obstacle to wound healing as discussed by the authors , which is called wound cleansing, debridement, edge refashioning, and dressing.
Abstract: In the management of chronic wounds, the concept of “wound hygiene” has emerged to effectively manage biofilms, an obstacle to wound healing. The core principles of wound hygiene are wound cleansing, debridement, edge refashioning, and dressing. Cleansing is the first step in wound hygiene and should be performed at every dressing change to reduce the bacterial load and prevent biofilm formation. It is also performed to remove remaining debris after debridement. Cleansing should be performed not only on the wound but also on the surrounding skin. In addition, in order to break down rigid biofilm barriers, surfactants or antiseptics should be actively used at an early stage. Antiseptics should have excellent broad-spectrum antibacterial activity and low cytotoxicity while also being hypoallergenic. Octenidine dihydrochloride, polyhexanide, and povidone-iodine have these properties and are suitable for use as cleansing solutions. To effectively manage chronic wound biofilms, it is important to select an appropriate antiseptic and cleanse vigorously with sufficient time for the antiseptic to work. In addition, taking wound hygiene procedures for granted and repeating them regularly and frequently will lay the foundation for promoting wound healing.
TL;DR: Wang et al. as discussed by the authors delineate the scientific output characteristics, research trends, hotspots and frontiers of high-throughput sequencing (HTS) technologies related to chronic wounds globally over the past 20 years.
Abstract: Background Chronic wounds are a complex medical problem. With the difficulty of skin healing, the microbial ecology of chronic wounds is an essential factor affecting wound healing. High-throughput sequencing (HTS) technology is a vital method to reveal the microbiome diversity and population structure of chronic wounds. Objective The aim of this paper was to delineate the scientific output characteristics, research trends, hotspots and frontiers of HTS technologies related to chronic wounds globally over the past 20 years. Methods We searched the Web of Science Core Collection (WoSCC) database for articles published between 2002 and 2022 and their full record information. The Bibliometrix software package was used to analyze bibliometric indicators and VOSviewer visualization analysis results. Results Ultimately, a total of 449 original articles were reviewed, and the results showed that the number of annual publications (Nps) about HTS associated with chronic wounds has steadily increased over the last 20 years. The United States and China produce the most articles and have the highest H-index, while the United States and England have the largest number of citations (Nc) in this field. The University of California, Wound Repair and Regeneration and National Institutes of Health Nih United States were the most published institutions, journals and fund resources, respectively. The global research could be divided into 3 clusters as follows: microbial infection of chronic wounds, the healing process of wounds and microscopic processes, skin repair mechanism stimulated by antimicrobial peptides and oxidative stress. In recent years, “wound healing”, “infections”, “expression”, “inflammation”, “chronic wounds”, “identification” and “bacteria” “angiogenesis”, “biofilms” and “diabetes” were the most frequently used keywords. In addition, research on “prevalence”, “gene expression”, “inflammation” and “infection” has recently become a hotspot. Conclusions This paper compares the research hotspots and directions in this field globally from the perspectives of countries, institutions and authors, analyzes the trend of international cooperation, and reveals the future development direction of the field and research hotspots of great scientific research value. Through this paper, we can further explore the value of HTS technology in chronic wounds to better solve the problem of chronic wounds.
TL;DR: In this paper , a hyaluronic acid (HA) microneedle embedded in a cerium/zinc-based nanomaterial (ZCO) was used for the treatment of diabetic wounds.
Abstract: Chronic nonhealing diabetic wounds are becoming increasingly severe, with high rates of mortality and disability, owing to the difficulty in wound healing caused by hyperglycemia, blocked angiogenesis, biofilm infection, and excessive oxidative stress. W e report a multicomponent enzyme-responsive natural polymer, a hyaluronic acid (HA) microneedle, embedded in a cerium/zinc-based nanomaterial (ZCO) for the treatment of diabetic wounds. ZCO-HA can destroy the oxidation balance of bacteria, kill bacteria, and scavenge reactive oxygen species (ROS) to alleviate oxidative stress via the adjustable release of Zn2+ and Ce3+ /4+ . Additionally, ZCO-HA exhibited good anti-inflammatory activity through the nuclear factor kappa-B (NF-κB) pathway, which reduces the inflammatory state of macrophages and promotes cell proliferation, migration, and angiogenesis. In vitro experiments shows that ZCO-HA accompanies mouse fibroblast migration, promoting human umbilical vein endothelial cell tube formation. In vivo studies in mice with streptozotocin-induced (STZ)-induced diabetes revealed that this microneedle accelerated wound healing without systemic toxicity. RNA transcriptome sequencing illustrated that the multicomponent HA microneedle accelerated wound healing in diabetes through cell migration and inhibited inflammatory reactions and oxidative damage in mice via the NF-κB signaling pathway. This article is protected by copyright. All rights reserved.
TL;DR: In this article , the authors determined the profile of chronic wounds in patients treated by the Department of Plastic Surgery Dr. Soetomo General Hospital Surabaya from 2015 to 2020 using total sampling technique, which consist of age, gender, past medical history, clinical features, diagnosis, management, and outcome.
Abstract: Background: Wounds that have lasted a long time due to failure to continue the normal healing process can be called chronic wounds. Chronic wounds occur due to multiple factors. There are problems that are often found in chronic wounds, such as the presence of exudate, necrotic tissue, and bacteria. The incidence of chronic wounds is closely related to the high cost of treatment and impaired quality of life. Prompt wound management is needed to optimize wound healing. Purpose: To determine the profile of chronic wounds in patients treated by the Department of Plastic Surgery Dr. Soetomo General Hospital Surabaya from 2015 – 2020. Methods: The data were obtained from patients medical records through total sampling technique, which consist of age, gender, past medical history, clinical features, diagnosis, management, and outcome. Result: This study involved 53 patients, dominated by male patients (70%) aged 46-65 years old (34%). The patient’s history showed that most patients suffered from type 2 diabetes (22%). The problem that often occurs is the presence of exudate which is mostly diagnosed with pressure ulcers (40%). All patient get wound bed preparation and the patient's outcome was dominated by recovery (72%). Conclusion: There are several factors affecting wound healing and prompt wound management are important to improving the outcomes.
TL;DR: Zhang et al. as discussed by the authors conducted a study to compare platelet-rich plasma (PRP) dressing with normal saline dressing in treating chronic wounds, and found that the complete healing rate of the PRP group was significantly higher than that of the normal saline group at 8 weeks and 12 weeks, respectively.
Abstract: Recently, many clinical trials have applied platelet-rich plasma (PRP) dressings to treat wounds that have stopped healing, which are also called chronic wounds. However, the clinical efficiency of PRP dressings in treating chronic wounds is still controversial. Therefore, we conducted this study to compare PRP dressings with normal saline dressings in treating chronic wounds. Relevant randomized controlled trials focusing on utilizing PRP dressings in treating chronic wounds were extracted from bibliographic databases. Finally, 330 patients with chronic wounds, reported in eight randomized controlled trials, were included in this study. In total, 169 out of 330 (51.21%) were treated with PRP dressings, and 161 out of 330 (48.79%) were treated with normal saline dressings. The pooled results showed that the complete healing rate of the PRP group was significantly higher than that of saline group at 8 weeks and 12 weeks, respectively. In addition, there were no significant differences in wound infection and adverse events. Compared with normal saline dressing, the PRP dressing could effectively enhance the prognosis of chronic wounds. Furthermore, the PRP did not increase wound infection rate or occurrence of adverse events as an available treatment for chronic wounds.
TL;DR: In this paper , an innovative supramolecular nanofiber hydrogel (Hydrogel-RL) harboring antimicrobial peptides was developed based on the novel arginine end-tagging peptide (Pep 6) from our recent study, triggering cross-linking.
Abstract: Chronic wound infection caused by multidrug-resistant bacteria is a major threat globally, leading to high mortality rates and a considerable economic burden. To address it, an innovative supramolecular nanofiber hydrogel (Hydrogel-RL) harboring antimicrobial peptides was developed based on the novel arginine end-tagging peptide (Pep 6) from our recent study, triggering cross-linking. In vitro results demonstrated that Hydrogel-RL can sustain the release of Pep 6 up to 120 h profiles, which is biocompatible and exhibits superior activity for methicillin-resistant Staphylococcus aureus (MRSA) biofilm inhibition and elimination. A single treatment of supramolecular Hydrogel-RL on an MRSA skin infection model revealed formidable antimicrobial activity and therapeutic effects in vivo. In the chronic wound infection model, Hydrogel-RL promoted mouse skin cell proliferation, reduced inflammation, accelerated re-epithelialization, and regulated muscle and collagen fiber formation, rapidly healing full-thickness skin wounds. To show its vehicle property for wound infection combined therapy, etamsylate, an antihemorrhagic drug, was loaded into the porous network of Hydrogel-RL, which demonstrated improved hemostatic activity. Collectively, Hydrogel-RL is a promising clinical candidate agent for functional supramolecular biomaterials designed for combating multidrug-resistant bacteria and rescuing stalled healing in chronic wound infections.
TL;DR: In this paper , the authors outline the latest research on fungi in chronic wounds and discuss challenges and future perspectives related to diagnosing and managing chronic wounds, and emphasize the importance of fungus in chronic wound infection.
Abstract: The occurrence of chronic wounds is a major global health issue. These wounds are difficult to heal as a result of disordered healing mechanisms. The most common types of chronic wounds are diabetic ulcers, pressure ulcers, arterial/venous ulcers and nonhealing surgical wounds. Although bacteria are an important cause of chronic nonhealing wounds, fungi also play a substantial role in them. The fungal infection rate varies with different chronic wound types, but overall, the prevalence of fungi is extremely underestimated in the clinical treatment and management of chronic wounds. Wounds and ulcers can be colonized by host cutaneous, commensal or environmental fungi and evolve into local infections, causing fungemia as well as invasive fungal disease. Furthermore, the fungi involved in nonhealing wound-related infections help commensal bacteria resist antibiotics and the host immune response, forcing wounds to become reservoirs for multiresistant species, which are considered a potential key factor in the microbial bioburden of wounds and ulcers. Fungi can be recalcitrant to the healing process. Biofilm establishment is the predominant mechanism of fungal resistance or tolerance to antimicrobials in chronic nonhealing wounds. Candida albicans yeast and Trichophyton rubrum filamentous fungi are the main fungi involved in chronic wound infection. Fungal species diversity and drug resistance phenotypes in different chronic nonhealing wound types will be emphasized. In this review, we outline the latest research on fungi in chronic wounds and discuss challenges and future perspectives related to diagnosing and managing chronic wounds.
TL;DR: In this article , the authors discuss the significant polymers used to make nanofibers, their manufacturing processes, and their antibacterial effectiveness against microorganisms that typically cause chronic wound infections.
Abstract: Treatment of a wound infection caused by a multidrug-resistant (MDR) bacterium is challenging since traditional medicine is incapable of curing such infections. As a result, there is a critical need to develop wound dressings resistant to MDR bacteria. Over half of diabetic and burn wounds showed clinical symptoms of infection. Diabetes is a metabolic disorder that may have various consequences, including chronic sores, vascular damage, and neuropathy. Microbial infection and oxidative stress to the fibroblast are common causes of slow and ineffective wound healing. Since wound healing and tissue repair are complex cascades of cellular activities, prompt and ordered healing is critical throughout this process. Despite advances in medication development and sophisticated formulations, treating persistent wound infections remains difficult. The drawbacks of administering antibiotics through the digestive system have motivated the development of enhanced therapeutic dressings with antibacterial activity and the application of antibiotics by localized administration. Antimicrobial wound dressings have great promise for reducing infection risk and improving the healing rate of chronic lesions. Most current research in skin tissue engineering focuses on developing three-dimensional scaffolds that mimic natural skin's extracellular matrix (ECM). Electrospinning is a well-established method for producing nanoscale fibers. It is a simple, cost-effective, reproducible, and efficient process for encapsulating hydrophobic and hydrophilic antimicrobial compounds in synthetic and natural polymeric carriers. This review discusses various nanofibers as novel delivery systems for antimicrobial compounds in chronic wound healing. We will discuss the significant polymers used to make nanofibers, their manufacturing processes, and, most importantly, their antibacterial effectiveness against microorganisms that typically cause chronic wound infections.
TL;DR: A recombinant proteolytic enzyme, isolated from maggot saliva, with fibrinolytic action has been investigated through a series of nonclinical toxicology and in-vitro/in-vivo pharmacology studies to explore its potential safety and efficacy as an enzymatic debridement agent for use in chronic wounds as discussed by the authors .
Abstract: A new recombinant proteolytic enzyme, isolated from maggot saliva, with fibrinolytic action has been investigated through a series of non‐clinical toxicology and in‐vitro/in‐vivo pharmacology studies to explore its potential safety and efficacy as an enzymatic debridement agent for use in chronic wounds. Studies indicate that the enzyme has a good safety profile. When locally administered, it is not detrimental to wound healing, is non‐sensitising and is rapidly inactivated in the systemic circulation. Adverse effects are limited, at very high concentrations, to transient erythema at the site of application. In‐vitro testing indicates that the enzyme, whilst selective for fibrin, has additional proteolytic action against collagen and elastin, with enzymatic action for all three substrates being dose dependent. In‐vivo, we used an established MRSA biofilm model, in which microbiological counts were used as a surrogate for debridement efficacy. Here, we showed that higher concentrations of the enzyme in a formulated proprietary gel, significantly reduced MRSA counts over a period of 2 to 14 days, and significantly improved the vascularity of the wound at 14 days. Together, these data support the potential for this maggot‐derived proteolytic enzyme as a clinically effective debriding agent.
TL;DR: In this paper , several non-antibiotic compounds, polyhexamethylene biguanide (PHMB), curcumin, retinol, polysorbate 40, ethanol, and D-α-tocopheryl polyethylene glycol succinate 1000 (TPGS) were screened for their antibacterial and antibiofilm capabilities.
Abstract: Chronic wounds and their treatment present a significant burden to patients and healthcare systems alike, with their management further complicated by bacterial infection. Historically, antibiotics have been deployed to prevent and treat infections, but the emergence of bacterial antimicrobial resistance and the frequent development of biofilms within the wound area necessitates the identification of novel treatment strategies for use within infected chronic wounds. Here, several non-antibiotic compounds, polyhexamethylene biguanide (PHMB), curcumin, retinol, polysorbate 40, ethanol, and D-α-tocopheryl polyethylene glycol succinate 1000 (TPGS) were screened for their antibacterial and antibiofilm capabilities. The minimum inhibitory concentration (MIC) and crystal violet (CV) biofilm clearance against two bacteria frequently associated with infected chronic wounds, Staphylococcus aureus and Pseudomonas aeruginosa, were determined. PHMB was observed to have highly effective antibacterial activity against both bacteria, but its ability to disperse biofilms at MIC levels was variable. Meanwhile, TPGS had limited inhibitory activity but demonstrated potent antibiofilm properties. The subsequent combination of these two compounds in a formulation resulted in a synergistic enhancement of their capability to kill both S. aureus and P. aeruginosa and disperse their biofilms. Collectively, this work highlights the utility of combinatory approaches to the treatment of infected chronic wounds where bacterial colonization and biofilm formation remains significant issues.
TL;DR: In this paper , an asymmetric electrospun nanofiber composed of polycaprolactone (PCL), chitosan (CS), and curcumin (Cur) was used as a chronic wound dressing.
Abstract: Chronic wounds are a growing medical issue around the world, with 2.4 - 4.5 million people afflicted in the United States alone. The condition currently makes up 2-3% of healthcare costs for developed countries, and this number is expected to increase as chronic wound-causing problems, like diabetes, grow in prevalence. Due to the lack of effective wound dressings, chronic wounds face a higher risk for bacterial infection and express high morbidity and mortality rates. Many current dressings are homogeneous and fail to account for the complexities of the different layers of skin. Alternatively, asymmetric electrospun nanofibers have a bilayer design that corresponds to the skin’s dermis and epidermis. We intend to demonstrate that an asymmetric electrospun nanofiber composed of polycaprolactone (PCL), chitosan (CS), and curcumin (Cur) can be utilized as a chronic wound dressing. These three biodegradable and biocompatible components were applied in an asymmetric design to mimic the protective epidermis and porous dermis. Upon electrospinning our asymmetric nanofiber and running it through a scanning electron microscope, we found that our hydrophobic PCL layer had a low porosity (52.16%) and thin nanofibers (281.82 nm), while our hydrophilic PCL/CS/Cur layer had a high porosity (61.18%) and thick nanofibers (425.54 nm). Our asymmetric nanofiber was also more effective at resisting bacterial permeation than the homogeneous PCL nanofiber. Our results highlight the superiority of asymmetric membranes for resisting bacterial infection and suggest that with further experimentation, we can establish our nanofiber as a viable wound dressing.
TL;DR: The appearance of modern dressings with the concept of moist wound healing has brought a completely new doctrine of their treatment, enabling significantly faster healing and thus a number of other benefits for health systems and health workers, patients with chronic wounds, and for society as a whole, reducing treatment costs drastically as mentioned in this paper .
Abstract: The appearance of modern dressings for the treatment of chronic wounds with the concept of moist wound healing has brought a completely new doctrine of their treatment, enabling significantly faster healing and thus a number of other benefits for health systems and health workers, patients with chronic wounds, and for society as a whole, reducing treatment costs drastically. The greatest benefit from their use is achieved by patients with chronic wounds, bearing in mind that a chronic wound significantly reduces and impairs the quality of life of patients. What makes modern dressings for the treatment of chronic wounds special is their simple use, which enables even family doctors to successfully treat chronic wounds with modern dressings, when the location of the wound itself and the involvement of frozen tissue allow it. They can be applied in the doctor's offices as well as in the patients' homes by the patrol services. Their application can be of particular importance to patients in rural areas where the health care system is more difficult to access and where the appointments of health workers, doctors and nurses are not daily. In those cases, patients, as well as their family members, can be educated to apply modern dressings for the treatment of chronic wounds by themselves with occasional control examinations by health workers.
TL;DR: In this paper , a microneedle (MN) patch was designed to achieve rapid wound healing via an efficient chemo-photodynamic antibacterial effect and sustained release of growth factors at the wound bed.
Abstract: Chronic wound healing is a major challenge in biomedicine. Conventional therapies are usually associated with poor drug permeability, low bioavailability, risk of antimicrobial resistance, and require frequent administration. Therefore, a novel formulation with a reduced antibiotic dosage, improved drug delivery efficiency, and low application frequency is of remarkable interest for chronic wound healing. Herein, we aimed to present a multifunctional microneedle (MN) patch to achieve rapid wound healing via an efficient chemo-photodynamic antibacterial effect and sustained release of growth factors at the wound bed. When the MN patch pierced the skin, MN tips carrying both a low dosage of antibiotics and bioactive small molecule-encapsulated metal-organic frameworks (MOFs) rapidly dissolved and subsequently delivered the payloads to the wound. Upon light irradiation, the MOF-based nanoparticles robustly converted O2 into 1 O2 , which acted synergistically with chemotherapy to remove pathogenic bacteria from the wound, exhibiting excellent chemo-photodynamic antibacterial performance with a 10-fold reduction in the required antibiotic amount. The nanoparticles could achieve a continuous release of growth factors in the wound tissue, promoting the formation of epithelial tissue and neovascularization, thereby further accelerating chronic wound healing. Collectively, the designed multifunctional MOF-based MN patches offer a simple, safe, and effective alternative for chronic wound management. This article is protected by copyright. All rights reserved.
TL;DR: Wang et al. as discussed by the authors designed sequence-specific, chemically modified antagomiR oligonucleotides (AMOs-198), which can effectively target miR-198.
TL;DR: In this paper , the authors review the distinguishing wound properties for these five common chronic nonhealing lower-extremity wounds and outline a comprehensive treatment plan that addresses wound perfusion, debridement, infection control, moisture balance, and use of complementary advanced wound care products.
01 Jan 2023
TL;DR: In this paper , various growth factor therapies that are used clinically to increase cell activities are described, including platelet-derived growth factor, basic fibroblast growth factor (bFGF), and epidermal growth factor for topical use on diabetic foot ulcers.
Abstract: Many of chronic wounds are delayed or fail to heal through conventional treatment because attenuated activities of cells responsible for wound healing contribute to the impairment of tissue restoration. The orderly and efficient progression of the wound healing sequence is orchestrated by intercellular communication, much of which is regulated by growth factors and cytokines. Consequently, there is a need for more effective therapy that will stimulate cellular activity of chronic wound patients. Recently, there has been much interest in treating these ulcers with various types of treatment modalities to stimulate cellular functions of chronic wound patients, including growth factors and cell therapies. It has long been hypothesized that using growth factors can promote healing of chronic wounds. Research is currently under way on methods to externally deliver growth factors depleted by diminished cell function in chronic wounds which would therefore facilitate healing; some of these are already being used in clinical settings. Products containing platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF) for topical use on diabetic foot ulcers are some examples. In this chapter, various growth factor therapies that are used clinically to increase cell activities are described.